, /PRNewswire/ -- Ridgetech, Inc. (Nasdaq:RDGT) ("Ridgetech" or the "Company"), a wholesale distributor of pharmaceutical and other healthcare products inChina, today announced its financial results for the fiscal year endedMarch 31, 2025.

, /PRNewswire/ -- Ridgetech, Inc. (Nasdaq:RDGT)（“Ridgetech” 或 “公司”），是一家在中国的药品及其他医疗产品的批发分销商，今天公布了截至2025年3月31日的财务业绩。

Mr. Frank Zhao, Interim Chief Executive Officer and Chief Financial Officer of Ridgetech, commented, "We are pleased to present a relatively stable revenue outcome for fiscal year 2025, a year marked by significant transformation for the Company. During this period, we divested our retail pharmacy business and acquired Ridgeline and its subsidiary, Allright (Hangzhou) Internet Technology Co. Ltd ("Allright"), marking our strategic expansion into both online and offline wholesale distribution of pharmaceutical and healthcare products in China.

Ridgetech 的临时首席执行官兼首席财务官 Frank Zhao 先生评论道：“我们很高兴地呈现 2025 财年的相对稳定的收入结果，这一年对公司而言是一个重大转型的年份。在此期间，我们剥离了零售药房业务，并收购了 Ridgeline 及其子公司 Allright（杭州）互联网科技有限公司（“Allright”），标志着我们在中国药品和医疗产品的线上和线下批发分销的战略扩展。

This move reflects our commitment to shift our resources focus onto the wholesale pharmaceutical sector, aligning with the evolving landscape and intensifying competition in China's healthcare industry. We believe Allright's broad and growing online and offline distribution network will rapidly become an indispensable contributor to our revenue and open up new business opportunities through its multiple platforms.

这一举措反映了我们将资源重点转向批发药品领域的承诺，以适应中国医疗行业不断变化的格局和日益激烈的竞争。我们相信 Allright 广泛且不断增长的线上和线下分销网络将迅速成为我们收入的重要贡献者，并通过其多个平台开辟新的商业机会。

Despite the scale of change in fiscal year 2025, we maintained stable total revenue of approximately US$120 million, while securing healthy profit margins across both our offline wholesale operations and online platforms. Notably, revenue from Allright's own and third-party online platforms -- only reflecting activity from March 2025 following our acquisition on February 28, 2025 -- already contributed nearly 1% of our total revenue, with a gross margin of 7.4%.

尽管 2025 财年发生了大规模的变化，我们仍保持了约 1.2 亿美元的稳定总收入，同时在我们的线下批发业务和在线平台上确保了健康的利润率。值得注意的是，Allright 自有及第三方在线平台的收入——仅反映我们在2025年2月28日收购后 2025 年 3 月的活动——已贡献了我们总收入的近 1%，毛利率为 7.4%。

To support this strategic shift, we increased our investment in sales and marketing by 64.2%, primarily to build a stronger foundation for post-transformation growth.

为了支持这一战略转型，我们将销售和市场营销的投资增加了 64.2%，主要是为了为转型后的增长奠定更强的基础。

Looking ahead, with the completion of our strategic transformation and continued progress in integrating our business segments and internal resources, we believe Ridgetech is now better positioned to drive long-term sustainable growth and deliver improved financial performance."

展望未来，随着我们战略转型的完成以及在整合业务部门和内部资源方面的持续进展，我们相信 Ridgetech 现在更有能力推动长期可持续增长并实现改善的财务表现。”

Fiscal Year 2025 Financial Summary

2025 财年财务摘要

In accordance with ASC 205, the Company has classified the historical retail operations, primarily conducted through Zhejiang Jiuxin Investment Management Co., Ltd. ("Jiuxin Investment") and its controlled entities, as discontinued operations and has re-presented prior periods accordingly. As a result, the comparative figures in this release reflect these adjustments and may differ from those previously reported.

根据 ASC 205，公司已将通过浙江九信投资管理有限公司（“九信投资”）及其控制实体主要进行的历史零售业务分类为终止经营，并相应地重新呈现了之前的期间。因此，本公告中的比较数据反映了这些调整，可能与之前报告的数据有所不同。

Revenue was$119.97 millionfor the fiscal year endedMarch 31, 2025, compared to$123.99 millionfor the same period of last year.
Gross profit was$3.84 millionfor the fiscal year endedMarch 31, 2025, compared to$4.88 millionfor the same period of last year.
Gross margin was 3.2% for the fiscal year endedMarch 31, 2025, compared to 3.9% for the same period of last year.
Net income was$10.20 million, or$1.84per basic and diluted earnings per share, for the fiscal year endedMarch 31, 2025, compared to net loss of$4.23 million, or$2.93per basic and diluted loss per share, for the same period of last year.

截至2025年3月31日的财年，收入为 1.1997 亿美元，较去年同期的 1.2399 亿美元下降。
截至2025年3月31日的财年，毛利润为 384 万美元，较去年同期的 488 万美元下降。
截至2025年3月31日的财年，毛利率为 3.2%，较去年同期的 3.9% 下降。
截至2025年3月31日的财年，净收入为 1020 万美元，或每股基本和稀释收益 1.84 美元，较去年同期的净亏损 423 万美元，或每股基本和稀释亏损 2.93 美元有所改善。

Fiscal Year 2025 Financial Results

2025 财年财务结果

Revenue

收入

Revenue decreased by$4.02 million, or 3.2%, to$119.97 millionfor the fiscal year endedMarch 31, 2025, from$123.99 millionfor the same period of last year.

截至2025年3月31日的财年，收入较去年同期下降 402 万美元，或 3.2%，降至 1.1997 亿美元，较去年同期的 1.2399 亿美元下降。

Revenue from offline wholesale decreased by$5.13 million, or 4.3%, to$118.86 millionfor the fiscal year endedMarch 31, 2025, from$123.99 millionfor the same period of last year. As a local wholesale distributor in pharmaceutical products, the Company's sales are limited to local and neighborhood regions. As the market became competitive, to keep reasonable profitability, the Company abandoned certain wholesales with low gross profit margin in the year ended March 31, 2025.As a result, the wholesale revenue declined.

线下批发收入较去年同期下降 513 万美元，或 4.3%，降至 1.1886 亿美元，较去年同期的 1.2399 亿美元下降。作为一家当地药品批发分销商，公司的销售仅限于本地和邻近地区。随着市场竞争加剧，为了保持合理的盈利能力，公司在截至2025年3月31日的财年放弃了某些毛利率较低的批发业务。因此，批发收入下降。

Revenue from Online platform increased to$1.11 millionfor the fiscal year endedMarch 31, 2025, fromnilfor the same period of last year. The increased figure reflects Allright's online platform revenue for the month of March, 2025. On February 28, 2025, the Company acquired Ridgeline and its subsidiary, Allright, which is a rapidly growing online and offline wholesale distributor of pharmaceutical and other healthcare products such as health foods, cosmetics and daily necessities in China. Allright actively trades on popular online distribution platforms nationwide. Through these online platforms, the Company sell various medical products to retail pharmacies, clinics and other vendors across the country. Allright also has its own online distribution platform.

截至2025年3月31日的财年，在线平台的收入增加至 111 万美元，较去年同期的零收入有所增长。增加的数字反映了 Allright 在 2025 年 3 月的在线平台收入。2025年2月28日，公司收购了 Ridgeline 及其子公司 Allright，后者是一家快速增长的药品及其他医疗产品的线上和线下批发分销商，产品包括保健食品、化妆品和日常必需品。Allright 在全国范围内的热门在线分销平台上积极交易。通过这些在线平台，公司向全国的零售药房、诊所和其他供应商销售各种医疗产品。Allright 还拥有自己的在线分销平台。

Gross profit and gross margin

毛利润和毛利率

Total cost of goods sold decreased to$116.13 millionfor the fiscal year endedMarch 31, 2025, from$119.12 millionfor the same period of last year. Gross profit decreased by$1.04million, or 21.3%, to$3.84million for the fiscal year endedMarch 31, 2025,from$4.88 millionfor the same period of last year. Overall gross margin decreased by 0.7 percentage points to 3.2% for the fiscal year endedMarch 31, 2025, from 3.9% for the same period of last year.

截至2025年3月31日的财年，商品销售总成本降至 1.1613 亿美元，较去年同期的 1.1912 亿美元下降。毛利润较去年同期下降 104 万美元，或 21.3%，降至 384 万美元。整体毛利率较去年同期下降 0.7 个百分点，降至 3.2%。

Gross margins for offline wholesale and online platform were 3.2% and 7.4%, respectively, for the fiscal year endedMarch 31, 2025, compared to gross margins for offline wholesale and online platform of 3.9% and nil%, respectively, for the same period of last year.

截至2025年3月31日的财年，线下批发和在线平台的毛利率分别为 3.2% 和 7.4%，而去年同期线下批发和在线平台的毛利率分别为 3.9% 和零。

Income (Loss) from operations

营业收入（亏损）

Sales and marketing expenses increased by$0.60 million, or 64.2%, to$1.53 millionfor the fiscal year endedMarch 31, 2025,from$0.93 millionfor the same period of last year. The increase was primarily attributable to the increase in drug distribution service fee. Overall, such expenses as a percentage of the Company's revenue were 1.3% and 0.8% respectively, for the years ended March 31, 2025 and 2024.

截至2025年3月31日的财年，销售和市场营销费用增加了 60 万美元，或 64.2%，达到 153 万美元，较去年同期的 93 万美元有所增加。增加的主要原因是药品分销服务费的增加。总体而言，这些费用占公司收入的比例分别为 1.3% 和 0.8%，适用于截至 2025 年和 2024 年的财年。

General and administrative expenses decreased by$8,158, or 0.2%, to$3.34million for the fiscal year endedMarch 31, 2025,from$3.35 millionfor the same period of last year. The decrease in general and administrative expenses was primarily due to the decrease in warehousing management fee, offset by the increase in exchange loss of approximately $0.51 million. Such expenses as a percentage of revenue increased for the year ended March 31, 2025 to 2.8% from 2.7% for the same period a year ago. In the year ended March 31, 2025, the Company recorded approximately $0.52 million in warehousing management fee as compared to approximately of $0.99 million in warehousing management fee in the year ended March 31, 2024.

一般和管理费用减少了 8,158 美元，或 0.2%，至 334 万美元，截止于2025年3月31日的财年，相比于去年同期的 335 万美元。一般和管理费用的减少主要是由于仓储管理费的减少，部分被约 51 万美元的汇兑损失所抵消。截止于2025年3月31日的财年，这些费用占收入的比例从去年同期的 2.7% 上升至 2.8%。在截止于2025年3月31日的财年，公司记录的仓储管理费约为 52 万美元，而在截止于2024年3月31日的财年为约 99 万美元。

Loss from operations was$1.04 millionfor the fiscal year endedMarch 31, 2025, compared toincome from operations of $0.60 millionfor the same period of last year. Operating margin was (0.9)% and 0.5% for the fiscal year endedMarch 31, 2025and 2024, respectively.

截止于2025年3月31日的财年，运营损失为 104 万美元，而去年同期的运营收入为 60 万美元。运营利润率分别为（0.9）% 和 0.5%。

Net loss from continuing operations

持续经营的净损失

Net loss from continuing operations was $1.45millionand $0.79 millionin the years ended March 31, 2025 and 2024.

截止于 2025 年和2024年3月31日的财年，持续经营的净损失分别为 145 万美元和 79 万美元。

Net income (loss)

净收入（损失）

Net income was$10.20 million, or$1.84per basic and diluted earnings per share for the fiscal year endedMarch 31, 2025, compared to net loss of$4.23 million, or$2.93per basic and diluted loss per share for the same period of last year.

截止于2025年3月31日的财年，净收入为 1,020 万美元，或每股基本和稀释收益 1.84 美元，而去年同期的净损失为 423 万美元，或每股基本和稀释损失 2.93 美元。

Financial Condition

财务状况

As of March 31, 2025, the Company had cash and cash equivalents of $12.78 million, compared to $2.30 million as of March 31, 2024. Net cash provided by operating activities was $1.25 million for the fiscal year ended March 31, 2025, compared to net cash used in operating activities of $3.16 million for the same period of last year. The change is primarily attributable to an increase in other payables and accrued liabilities of $27.88 million, an increase in accounts receivable of $11.84 million and an increase in net income (loss) of $14.43 million, offset by a decrease in accounts payable of $27.13 million, a decrease in other receivable of $11.09 million and a decrease in gain of divestiture of Jiuxin Investment of $15.76 million.

截至2025年3月31日，公司拥有现金及现金等价物 1,278 万美元，而截至2024年3月31日为 230 万美元。截止于2025年3月31日的财年，经营活动提供的净现金为 125 万美元，而去年同期的经营活动使用的净现金为 316 万美元。变化主要归因于其他应付款和应计负债增加了 2,788 万美元，应收账款增加了 1,184 万美元，以及净收入（损失）增加了 1,443 万美元，部分被应付账款减少了 2,713 万美元、其他应收款减少了 1,109 万美元以及九信投资剥离收益减少了 1,576 万美元所抵消。

Net cash used in investing activities was$18.14 millionfor the fiscal year endedMarch 31, 2025, compared to$2.04 millionfor the same period of last year. The change is primarily attributable to divestiture of Jiuxin Investment.

截止于2025年3月31日的财年，投资活动使用的净现金为 1,814 万美元，而去年同期为 204 万美元。变化主要归因于九信投资的剥离。

Net cash provided by financing activities was$1.51 millionfor the fiscal year endedMarch 31, 2025, compared to$8.00 millionfor the same period of last year. The change is primarily due to proceeds from equity and debt financing and change in notes payables issued to Hangzhou United Bank.

截止于2025年3月31日的财年，融资活动提供的净现金为 151 万美元，而去年同期为 800 万美元。变化主要是由于从股权和债务融资中获得的收益以及向杭州联合银行发行的票据的变化。

AboutRidgetech, Inc.

关于 Ridgetech, Inc.

Ridgetech, Inc., formerly known asChina Jo-JoDrugstores, Inc. ("Ridgetech" or the "Company"), is a growing online and offline wholesale distributor of pharmaceutical and other healthcare products in China. Ridgetech actively trades on popular online distribution platforms nationwide and has its own online distribution platform. The Company believes that trading on these platforms offers greater opportunities to distribute pharmaceutical products nationwide. For more information about the Company, please visitwww.ridgetch.com. The Company routinely posts important information on its website.

Ridgetech, Inc.，前身为 China Jo-Jo Drugstores, Inc.（"Ridgetech"或"公司"），是中国一家不断发展的在线和离线药品及其他医疗保健产品的批发分销商。Ridgetech 在全国范围内的热门在线分销平台上积极交易，并拥有自己的在线分销平台。公司认为，在这些平台上交易提供了更大的机会来在全国范围内分销药品。有关公司的更多信息，请访问 www.ridgetch.com。公司定期在其网站上发布重要信息。

Forward-Looking Statements

前瞻性声明

This press release contains information about the Company's view of its future expectations, plans and prospects that constitute forward-looking statements. Forward-looking statements usually, but not always, contain the words "estimate," "anticipate," "believe," "expect," or similar expressions, or the negative of those words and expressions, as well as statements in future tense. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the Company. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with the Company's ability to secure additional funding, execute its business strategy, and respond to changing market conditions; fluctuations in operating results; the Company's ability to maintain and grow its distribution platforms and customer base; the Company's dependence on key customers; the effectiveness of marketing and business development efforts; the integration of acquired businesses, technologies, or assets; intensifying competition within the pharmaceutical and healthcare distribution industry; evolving government regulations and macro-economic conditions in China and globally; its ability to attract, hire, and retain qualified management and employees; and the adequacy of its intellectual property protection. The Company encourages you to review other factors that may affect its future results in the Company's annual reports and in its other filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or publicly announce revisions to any forward-looking statements to reflect future events or developments, except as required by law.

本新闻稿包含有关公司对其未来预期、计划和前景的看法，这些内容构成前瞻性声明。前瞻性声明通常，但并不总是，包含 “估计”、“预期”、“相信”、“期待” 或类似表达，或这些词和表达的否定，以及未来时态的陈述。所有前瞻性声明本质上都是不确定的，因为它们基于对未来事件或公司未来表现的当前预期和假设。实际结果可能因多种因素而与历史结果或这些前瞻性声明所指示的结果有重大差异，包括但不限于与公司获得额外资金、执行其商业战略和应对市场条件变化的能力相关的风险和不确定性；运营结果的波动；公司维持和扩大其分销平台和客户基础的能力；公司对关键客户的依赖；市场营销和业务发展工作的有效性；收购业务、技术或资产的整合；制药和医疗保健分销行业的竞争加剧；中国及全球政府法规和宏观经济条件的变化；吸引、雇用和留住合格管理人员和员工的能力；以及其知识产权保护的充分性。公司鼓励您查看可能影响其未来结果的其他因素，这些因素在公司的年度报告和向证券交易委员会的其他文件中有所披露。除法律要求外，公司不承担更新或公开宣布对任何前瞻性声明进行修订以反映未来事件或发展的义务。

For more information, please contact:

如需更多信息，请联系：

Company Contact:

公司联系人：

Frank Zhao

Chief Financial Officer

首席财务官

+86-571-88077108

frank.zhao@ridgetch.com

Investor Relations Contact:

投资者关系联系人：

Tina Xiao Ascent Investor Relations LLC

+1-646-932-7242

investors@ascent-ir.com


RIDGETECH, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS

	March31,		March31,
	2025		2024
ASSETS
CURRENT ASSETS
Cash and cash equivalents	$	12,779,781		$	2,297,256
Restricted cash		5,761,294			1,988,710
Trade accounts receivables		27,811,813			6,014,511
Inventories		9,758,071			9,076,734
Other receivables, net		2,419,671			218,765
Advances to suppliers		433,140			182,075
Due from related parties		-			19,737
Other current assets		745,477			-
Current assets of discontinued operations		-			49,884,574
Total current assets		59,709,247			69,682,362

NON-CURRENT ASSETS
Property and equipment, net		8,931			8,377
Intangible assets, net		3,302,961			1,276,737
Goodwill		1,463,733			-
Non-current assets of discontinued operations		-			24,089,614
Total non-current assets		4,775,625			25,374,728
Total assets	$	64,484,872		$	95,057,090

LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES
Accounts payable	$	19,666,664		$	30,576,909
Notes payable		10,386,612			6,594,442
Other payables		2,319,139			592,876
Due to related parties		2,130			2,140
Customer deposits		264,068			174,138
Taxes payable		1,521,546			543,081
Accrued liabilities		196,210			197,199
Current liabilities of discontinued operations		-			35,679,310
Total current liabilities		34,356,369			74,360,095

NON-CURRENT LIABILITIES
Deferred tax liabilities		492,121			-
Non-current liabilities of discontinued operations		-			6,403,858
Total non-current liabilities		492,121			6,403,858
Total liabilities		34,848,490			80,763,953

COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS' EQUITY
Ordinary shares; $0.24 par value; 36,000,000,000 shares authorized; 5,855,009 and 1,743,362 shares issued and outstanding as of March 31, 2025 and 2024, respectively		1,405,202			418,407
Preferred shares; $0.001 par value; 10,000,000 shares authorized; nil issued and outstanding as of March 31, 2025 and 2024		-			-
Additional paid-in capital		91,743,163			86,413,978
Statutory reserves		-			1,309,109
Accumulated deficit		(63,312,779)			(73,507,246)
Accumulated other comprehensive income		(199,204)			1,005,762
Total shareholders' equity attributed to Ridgetech		29,636,382			15,640,010
Noncontrolling interests		-			(1,346,873)
Total shareholders' equity		29,636,382			14,293,137
Total liabilities and shareholders' equity	$	64,484,872		$	95,057,090


RIDGETECH, INC. 及其子公司
合并资产负债表

	2025年3月31日		2024年3月31日

资产
流动资产
现金及现金等价物	$	12,779,781		$	2,297,256
限制性现金		5,761,294			1,988,710
应收账款		27,811,813			6,014,511
存货		9,758,071			9,076,734
其他应收款，净额		2,419,671			218,765
预付款项		433,140			182,075
应收关联方款项		-			19,737
其他流动资产		745,477			-
停业业务的流动资产		-			49,884,574
流动资产总计		59,709,247			69,682,362

非流动资产
净物业和设备		8,931			8,377
净无形资产		3,302,961			1,276,737
商誉		1,463,733			-
停业业务的非流动资产		-			24,089,614
非流动资产总计		4,775,625			25,374,728
资产总计	$	64,484,872		$	95,057,090

负债及股东权益
流动负债
应付账款	$	19,666,664		$	30,576,909
应付票据		10,386,612			6,594,442
其他应付款		2,319,139			592,876
应付关联方款项		2,130			2,140
客户存款		264,068			174,138
应付税款		1,521,546			543,081
应计负债		196,210			197,199
停业业务的流动负债		-			35,679,310
流动负债总计		34,356,369			74,360,095

非流动负债
递延所得税负债		492,121			-
停业业务的非流动负债		-			6,403,858
非流动负债总计		492,121			6,403,858
负债总计		34,848,490			80,763,953

承诺与或有事项
股东权益
普通股；面值$0.24；授权 36,000,000,000 股；
截至2025年3月31日和2024年3月31日，已发行和流通 5,855,009 股和 1,743,362 股		1,405,202			418,407
优先股；面值$0.001；授权 10,000,000 股；截至2025年3月31日和2024年3月31日，未发行和流通		-			-
额外实收资本		91,743,163			86,413,978
法定储备		-			1,309,109
累计亏损		(63,312,779)			(73,507,246)
累计其他综合收益		(199,204)			1,005,762
归属于 Ridgetech 的股东权益总计		29,636,382			15,640,010
非控股权益		-			(1,346,873)
股东权益总计		29,636,382			14,293,137
负债及股东权益总计	$	64,484,872		$	95,057,090


RIDGETECH, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

	For the years ended March 31,
	2025		2024			2023
REVENUES, NET	$	119,971,638		$	123,994,053		$	120,199,193

COST OF GOODS SOLD		116,132,823			119,115,636			116,597,751

GROSS PROFIT		3,838,815			4,878,417			3,601,442

SELLING EXPENSES		1,534,200			934,223			1,266,025
GENERAL AND ADMINISTRATIVE EXPENSES		3,339,954			3,348,112			5,137,741
STOCK BASED COMPENSATION		-			-			10,360,000
TOTAL OPERATING EXPENSES		4,874,154			4,282,335			16,763,766

INCOME (LOSS) FROM OPERATIONS		(1,035,339)			596,082			(13,162,324)

OTHER INCOME (EXPENSES):
INTEREST INCOME		92,834			197,763			31,582
INVESTMENT LOSS		-			(1,607,537)			(2,402,376)
OTHER INCOME (EXPENSES)		(8,155)			(13,377)			92,358

LOSS BEFORE INCOME TAXES		(950,660)			(827,069)			(15,440,760)

PROVISION FOR INCOME TAXES		503,524			(41,363)			394,541
NET LOSS FROM CONTINUING OPERATIONS		(1,454,184)			(785,706)			(15,835,301)
NET LOSS FROM DISCONTINUED OPERATIONS, NET OF TAXES		(4,103,718)			(3,448,536)			(5,303,476)
GAIN OF DIVESTITURE JIUXIN INVESTMENT		15,757,753			-			-
NET GAIN(LOSS) FROM DISCONTINUED OPERATIONS, NET OF TAX		11,654,035			(3,448,536)			(5,303,476)

NET INCOME (LOSS)		10,199,851			(4,234,242)			(21,138,777)

LESS: NET LOSS ATTRIBUTABLE TO NONCONTROLLING INTEREST		5,384			(14)			(252)

NET INCOME (LOSS) ATTRIBUTABLE TO RIDGETECH, INC.		10,194,467			(4,234,228)			(21,138,525)
NET INCOME (LOSS) ATTRIBUTABLE TO RIDGETECH, INC. FROM CONTINUING OPERATIONS		(1,454,184)			(785,706)			(15,835,301)
NET INCOME (LOSS) ATTRIBUTABLE TO RIDGETECH, INC. FROM DISCONTINUED OPERATIONS		11,648,651			(3,448,522)			(5,303,224)

OTHER COMPREHENSIVE LOSS
FOREIGN CURRENCY TRANSLATION ADJUSTMENTS		(1,204,966)			(729,373)			(2,617,857)
COMPREHENSIVE INCOME (LOSS)		8,994,885			(4,963,615)			(23,756,634)

WEIGHTED AVERAGE NUMBER OF SHARES:
Basic		5,543,118			1,444,263			509,828
Diluted		5,543,118			1,444,263			509,828

INCOME (LOSS) PER SHARE:
Basic	$	1.84		$	(2.93)		$	(41.46)
Diluted	$	1.84		$	(2.93)		$	(41.46)


RIDGETECH, INC. 及其子公司
合并经营报表及综合收益（损失）

	截至
	2025年3月31日		2024 年			2023 年
净收入	$	119,971,638		$	123,994,053		$	120,199,193

销售成本		116,132,823			119,115,636			116,597,751

毛利润		3,838,815			4,878,417			3,601,442

销售费用		1,534,200			934,223			1,266,025
一般及行政费用		3,339,954			3,348,112			5,137,741
股票基础补偿		-			-			10,360,000
总运营费用		4,874,154			4,282,335			16,763,766

运营收入（损失）		(1,035,339)			596,082			(13,162,324)

其他收入（费用）：
利息收入		92,834			197,763			31,582
投资损失		-			(1,607,537)			(2,402,376)
其他收入（费用）		(8,155)			(13,377)			92,358

税前损失		(950,660)			(827,069)			(15,440,760)

所得税费用		503,524			(41,363)			394,541
持续经营的净损失		(1,454,184)			(785,706)			(15,835,301)
停业经营的净损失，
扣除税费		(4,103,718)			(3,448,536)			(5,303,476)
处置 Jiuxin 投资的收益		15,757,753			-			-
停业经营的净收益（损失），扣除税费		11,654,035			(3,448,536)			(5,303,476)

净收益（损失）		10,199,851			(4,234,242)			(21,138,777)

减：归属于
非控股权益的净损失		5,384			(14)			(252)

归属于 RIDGETECH, INC. 的净收益（损失）		10,194,467			(4,234,228)			(21,138,525)
归属于 RIDGETECH, INC. 的持续经营的净收益（损失）		(1,454,184)			(785,706)			(15,835,301)
归属于 RIDGETECH, INC. 的停业经营的净收益（损失）		11,648,651			(3,448,522)			(5,303,224)

其他综合损失
外币翻译调整		(1,204,966)			(729,373)			(2,617,857)
综合收益（损失）		8,994,885			(4,963,615)			(23,756,634)

加权平均股份数：
基本		5,543,118			1,444,263			509,828
稀释		5,543,118			1,444,263			509,828

每股收益（损失）：
基本	$	1.84		$	(2.93)		$	(41.46)
稀释	$	1.84		$	(2.93)		$	(41.46)


RIDGETECH, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS

	For the years ended March 31,
	2025		2024			2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	10,199,851		$	(4,234,242)		$	(21,138,777)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		1,137,240			790,449			718,002
Bad debt direct write-off and provision and reversal		85,642			(249,257)			7,579,886
Amortization of right-of-use assets		4,879,012			4,594,172			-
Loss from disposal of property and equipment		-			107,251			-
Gain of divestiture Jiuxin Investment		(15,757,753)			-			-
Deferred tax expenses(benefits)		(29,822)
Share-based compensation		-			-			10,360,000
Investment loss		-			1,607,537			2,402,376
Change in operating assets and liabilities:
Accounts receivable		10,040,414			(1,804,440)			(2,531,755)
Notes receivable		(29,271)			19,943			(20,861)
Inventories and biological assets		405,822			(1,699,621)			(522,550)
Other receivables		(11,758,658)			(672,830)			(958,671)
Advances to suppliers		(341,702)			(839,221)			201,984
Long term deposit		(1,361,613)			(132,568)			589,653
Other current assets		-			19,076			331,426
Other noncurrent assets		(359,114)			69,539			(30,483)
Amount due from related parties		-			(317,828)			-
Accounts payable		(21,128,762)			6,002,186			1,765,488
Other payables and accrued liabilities		28,752,570			868,975			(1,426,829)
Customer deposits		(162,940)			(144,761)			(1,035,456)
Taxes payable		1,314,644			(948,277)			433,054
Operating lease liabilities		(4,637,790)			(6,191,522)			-
Net cash provided by (used in) operating activities		1,247,770			(3,155,439)			(3,283,513)

CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of equipment and building		(155,360)			(330,677)			(118,272)
Investment in a joint venture		-			(1,116,212)			(4,379)
Purchases of intangible assets		-			(66,973)			(12,774)
Additions to leasehold improvements		(459,907)			(525,988)			(180,672)
Acquisition of Ridgeline, net of cash acquired		4,833,439			-			-
Divestiture Jiuxin Investment, net of cash disposed		(22,353,250)			-			-
Net cash used in investing activities		(18,135,078)			(2,039,850)			(316,097)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from short-term bank loan		-			1,116,212			-
Repayment of short-term bank loan		(277,266)			(837,159)			-
Repayment of third parties loan		-			-			(1,811,558)
Proceeds from notes payable		51,689,531			56,875,403			57,965,013
Repayment of notes payable		(56,365,693)			(52,997,171)			(60,273,598)
Proceeds from issuance of shares and warrants in private placements		7,633,000			2,589,600			7,325,000
Proceeds from other payable-related parties		325,784			1,257,406			43,785
Repayment of other payable-related parties		(1,499,764)			-			(882,486)
Net cash provided by financing activities		1,505,592			8,004,291			2,366,156

EFFECT OF EXCHANGE RATE ON CASH		1,048,620			(1,505,475)			(2,535,479)

DECREASE (INCREASE) IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH		(14,333,096)			1,303,527			(3,768,933)
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, beginning of year		32,874,171			31,570,644			35,339,577
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, end of year	$	18,541,075		$	32,874,171		$	31,570,644

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for income taxes	$	137,456		$	149,023		$	63,668
Cash paid for interest		6,289			13,604			64,943

NON-CASH ACTIVITIES：
Cashless exercise of warrants	$	-		$	-		$	135,118
Issuance of shares for acquisition of subsidiaries		3,582,250			-			-
Cancellation of shares for disposal of subsidiaries		4,102,848			-			-


RIDGETECH, INC. 及其子公司
合并现金流量表

	截至
2025年3月31日的年度
	2025		2024			2023
经营活动产生的现金流量：
净亏损	$	10,199,851		$	(4,234,242)		$	(21,138,777)
调整净亏损以对账用于经营活动的净现金：
折旧和摊销		1,137,240			790,449			718,002
坏账直接冲销及准备金和冲回		85,642			(249,257)			7,579,886
使用权资产摊销		4,879,012			4,594,172			-
处置物业和设备的损失		-			107,251			-
处置九信投资的收益		(15,757,753)			-			-
递延税费（收益）		(29,822)
基于股份的补偿		-			-			10,360,000
投资损失		-			1,607,537			2,402,376
经营资产和负债的变动：
应收账款		10,040,414			(1,804,440)			(2,531,755)
应收票据		(29,271)			19,943			(20,861)
存货和生物资产		405,822			(1,699,621)			(522,550)
其他应收款		(11,758,658)			(672,830)			(958,671)
预付款项		(341,702)			(839,221)			201,984
长期存款		(1,361,613)			(132,568)			589,653
其他流动资产		-			19,076			331,426
其他非流动资产		(359,114)			69,539			(30,483)
应收关联方款项		-			(317,828)			-
应付账款		(21,128,762)			6,002,186			1,765,488
其他应付款和应计负债		28,752,570			868,975			(1,426,829)
客户存款		(162,940)			(144,761)			(1,035,456)
应付税款		1,314,644			(948,277)			433,054
经营租赁负债		(4,637,790)			(6,191,522)			-
经营活动提供（使用）的净现金		1,247,770			(3,155,439)			(3,283,513)

投资活动产生的现金流量：
设备和建筑物的收购		(155,360)			(330,677)			(118,272)
对合资企业的投资		-			(1,116,212)			(4,379)
无形资产的购买		-			(66,973)			(12,774)
租赁改善的增加		(459,907)			(525,988)			(180,672)
收购 Ridgeline，扣除收购现金		4,833,439			-			-
处置九信投资，扣除处置现金		(22,353,250)			-			-
投资活动使用的净现金		(18,135,078)			(2,039,850)			(316,097)

融资活动产生的现金流量：
短期银行贷款的收入		-			1,116,212			-
短期银行贷款的偿还		(277,266)			(837,159)			-
第三方贷款的偿还		-			-			(1,811,558)
应付票据的收入		51,689,531			56,875,403			57,965,013
应付票据的偿还		(56,365,693)			(52,997,171)			(60,273,598)
私募发行股份和认股权证的收入		7,633,000			2,589,600			7,325,000
其他应付款 - 关联方的收入		325,784			1,257,406			43,785
其他应付款 - 关联方的偿还		(1,499,764)			-			(882,486)
融资活动提供的净现金		1,505,592			8,004,291			2,366,156

汇率对现金的影响		1,048,620			(1,505,475)			(2,535,479)

现金及现金等价物和受限现金的减少（增加）		(14,333,096)			1,303,527			(3,768,933)
现金及现金等价物和受限现金，年初		32,874,171			31,570,644			35,339,577
现金及现金等价物和受限现金，年末	$	18,541,075		$	32,874,171		$	31,570,644

现金流量信息的补充披露：
支付的所得税	$	137,456		$	149,023		$	63,668
支付的利息		6,289			13,604			64,943

非现金活动：
无现金行使认股权证	$	-		$	-		$	135,118
为收购子公司而发行股份		3,582,250			-			-
为处置子公司而取消股份		4,102,848			-			-


(a)		The cash flows related to discontinued operations have not been segregated. Accordingly, the Consolidated Statements of Cash Flows include the results of continuing and discontinued operations.


(a)		与终止运营相关的现金流未被分开。因此，合并现金流量表包括持续运营和终止运营的结果。

SOURCE Ridgetech, Inc.

来源 Ridgetech, Inc.

Ridgetech 公司发布 2025 财年财务报告 | RDGT 股票新闻